ATROPINE 1 POUR CENT FAURE clinical trials

Safety and Efficacy of a Unilateral Subretinal Administration of HORA PDE6B in Patients with Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression

This study is testing a new gene therapy for people with retinitis pigmentosa caused by a specific faulty gene. It's looking at how safe the treatment is and if it helps improve vision. Researchers are giving the treatment into one eye.